Hidradenitis suppurativa promise sends Moonlake soaring
Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.
Cartesian maps the path for an autoimmune disease cell therapy
The private group celebrates a double first for its mRNA-generated Car-T therapy in myasthenia gravis.
Lilly gambles on Dice
Lilly follows others into the oral autoimmune space, not long after its leader questioned the future of small molecules.
Car-T beyond cancer? Novartis and others say yes
Putting Car-T therapy to work in autoimmune diseases has caught the attention of several biotech and big pharma groups.
Hope springs for April inhibition
Novartis’s Chinook takeout gives a boost to others pursuing this long-researched target, including Vera and Alpine.
Delays fail to Quell Treg interest
Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.